{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Possibly Marketed Outside US
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Class:
PROTEIN
Corticorelin (Xerecept) is a synthetic analog of the naturally occurring human peptide corticotropin-releasing factor (CRF). Corticotropin-releasing factor is the predominant regulator of adrenocorticotropic-hormone (ACTH) formation and release by the pituitary. In addition to its primary location in the hypothalamic paraventricular nucleus, endogenous CRF has also been identified in cerebral cortical interneurons, the limbic system, brain stem and spinal cord. Several studies have indicated the ability of CRF to reduce the brain edema caused by brain tumors. Clinical trials with the Corticorelin (Xerecept) have indicated that this drug has a distinct advantage over classical corticosteroids in the treatment of brain edema. Fewer and/or milder side effects have been reported for corticorelin compared with dexamethasone, although at higher doses of corticorelin several side effects, including hypotension and transient flushing, have been reported.
Status:
Possibly Marketed Outside US
Source:
BLA125796
(2024)
Source URL:
First approved in 2024
Source:
BLA125796
Source URL:
Class:
NUCLEIC ACID
Status:
Possibly Marketed Outside US
Source:
505G(a)(3)
(2024)
Source URL:
First approved in 2024
Source:
505G(a)(3)
Source URL:
Class:
NUCLEIC ACID
Status:
Possibly Marketed Outside US
Source:
Moderna COVID-19 Vaccine by Moderna US, Inc.
(2023)
Source URL:
First approved in 2023
Source:
Moderna COVID-19 Vaccine by Moderna US, Inc.
Source URL:
Class:
NUCLEIC ACID
Status:
Possibly Marketed Outside US
Source:
BLA125761
(2023)
Source URL:
First approved in 2023
Source:
BLA125761
Source URL:
Class:
NUCLEIC ACID
Status:
Possibly Marketed Outside US
Source:
BLA125752
(2022)
Source URL:
First approved in 2022
Source:
BLA125752
Source URL:
Class:
NUCLEIC ACID
Status:
Possibly Marketed Outside US
Source:
BLA125742
(2021)
Source URL:
First approved in 2021
Source:
BLA125742
Source URL:
Class:
NUCLEIC ACID
Status:
Possibly Marketed Outside US
Source:
BLA125742
(2021)
Source URL:
First approved in 2021
Source:
BLA125742
Source URL:
Class:
NUCLEIC ACID
Status:
Possibly Marketed Outside US
Source:
BLA125428
(2017)
Source URL:
First approved in 2017
Source:
BLA125428
Source URL:
Class:
NUCLEIC ACID